| My Account | Sitemap | Subscribe | Contact Us | ||
|
Diabetes Health
Diabetes Health Professional
- Taken for Health or Taken for a Ride?
Are vitamins and supplements really necessary for people with diabetes? John White discusses the nature and eff ects of the most common ones people take in addition to their medications.
- Cinnamon: Should It Be Taken as a Medication?
The verdict is in, says John White: Despite some intriguing initial results, subsequent studies have pretty much laid to rest cinnamon’s reputation as a pseudo-insulin.
- Sweeter (and Better) Than Sugar?
There are so many non-sugar sweeteners out there – where to begin? Well, begin here as the famous medical duo of Drs. Michael and Mary Dan Eades explore the pros and cons of various artifi cial sweeteners.
- Belly Busters for Beginners
Out of shape? Want to get better? Well, working your abdominals to get them into fi ghting trim is the classic way to start an exercise program. Ann Swank tells you how.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Diabetes Health Digital Advantage™, the free, online version of Diabetes Health magazine, virtually identical to the bi-monthly Diabetes Health print magazine, has many additional useful features.
While the pages turn in a similar fashion to a magazine's, direct hot links lead to research articles, products and advertiser sites.
Access to the amazing Diabetes Health Digital Advantage™ is through any web browser, so you can read the current issue of Diabetes Health magazine online wherever you are!
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Latest Type 1 Issues Articles
Pfizer Halts Sales of Exubera In Wake of Lung Cancer Fears
In wake of news that its inhaled insulin product Exubera has been linked to lung cancer, Pfizer Inc. has announced that it will cease manufacturing the drug and update labels on the remaining product to carry a cancer warning.
The company revealed that in a study of 4,740 patients taking Exubera, six developed lung cancer (1 out of every 780). In comparison, one out of 4,292 patients in the study who were not taking Exubera developed lung cancer.
Pfizer introduced Exubera in 2006 as the first inhaled insulin product on the market. By 2007, however, the company announced that it would cease marketing the product because of low demand. An estimated 4,000 people with diabetes worldwide are taking the drug.
Before receiving FDA approval to market Exubera, the drug’s apparent effects on lung function had been noted in studies – a concern that delayed approval for several years.
Inhaled insulin has been a kind of Holy Grail for pharmaceutical manufacturers since it avoids the pain and inconvenience of needle injections. When Pfizer ceased marketing Exubera last year, Novo Nordisk and Eli Lilly soon dropped their inhaled insulin development programs.
Valencia, Calif.-based MannKind Corp. has said it will continue work on its Technosphere inhaled insulin product.
Addendum:
Oramed Begins Studies on Oral Insulin Capsule
Israeli company Oramed Pharmaceuticals, Inc., a developer of oral delivery systems, has commenced Phase 2A studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem. The trial will focus on assessing the safety and efficacy of the capsule on 10 type 2 diabetes patients. This study is a continuation of the recently successfully completed Phase 1 studies in Israel.
Share on Facebook
Share on MySpace 
Share on Digg
You May Also Be Interested In...
837 comments - 26 Apr 2007
146 comments - 29 Nov 2007
76 comments - 13 Mar 2007
73 comments - 10 Apr 2008
63 comments - 23 Feb 2008
53 comments - 18 Jan 2008
Comments...
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register..
Register your Diabetes Health Username here.
Pfizer stopped manufacturing Exubera several months ago when they closed the plant and laid off a few hundred people. Check your press releases, Patrick!!
I want to know with what mechanism and what speed inhaled insulin may produce cancer, as you know rate of lung cancer is not increased in diabetics.This idea of possible cancerogen potential needs more study.
The implication of your headline is false. Please be historically accurate.
They JUST announced they were going to pull it in Europe in the past month or so. At least I think it was Exubera that I read about here iN Germany. It seems not all markets are identical to the US market, so it's possible Patrick's not so off. Regarding the article, though... sheesh! Going from 1 in 5,000 to 1 in 780? Eeek. The second they came out with that stuff I was afraid they'd try to make us take it instead of shots or something. No way! Shots are one thing, but messing with your lungs is another. I'm GLAD this stuff is going, going, GONE!
Exubera, even if it happened to be entirely safe, misses the point and is the real reason it was pulled from the market. Pfizer was betting that we are all miserable from taking insulin by injection, and that we would beat down the pharmacy doors to grab their insulin "bong" (as one diabetes blogger put it). Instead we have mostly stuck with the tried and true. Injections don't hurt as much as bad marketing. We don't need another short acting insulin (inhaled, oral, or whatever) as much as we need tools that provide improved glucose control, like the insulin pump, constant glucose monitoring, and (given enough time) replacement beta cells that are encapsulated and thus protected from the immune system.
Also, the more recent news on Exubera is that Nektar, who partnered with Pfizer to develop and market it, is giving up on it as well.
From all I've read and seen, Exubera delivery is bulky and cumbersome and therefore not well accepted by people who use insulin since other insulin delivery devices are much more convenient. I would like further information about the cancer connection...the actual research study would be great.
Have Your Say...